Share your videos with the world

Alstom today inaugurated its new hydropower manufacturing facility at Tianjin in China. The new factory will place Alstom in a better position to supply its customers in China and abroad, while offering opportunities for further expansion in China’s healthy hydropower market, which accounts for 22% of the country’s electricity generation capacity and is expanding at a rate of 15 GW per year. To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/alstom/47004/

Alstom today inaugurated its new hydropower manufacturing facility at Tianjin in China. The new factory will place Alstom in a better position to supply its customers in China and abroad, while offering opportunities for further expansion in China’s healthy hydropower market, which accounts for 22% of the country’s electricity generation capacity and is expanding at a rate of 15 GW per year. To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/alstom/47004/

GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience. To view the multimedia release go to: https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/